% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Slavc:182306,
      author       = {I. Slavc and L. Mayr and N. Stepien and J. Gojo and M.
                      Aliotti Lippolis and A. A. Azizi and M. Chocholous and A.
                      Baumgartner and C. S. Hedrich and S. Holm and A. Sehested
                      and P. Leblond and K. Dieckmann and C. Haberler and T. Czech
                      and M. Kool$^*$ and A. Peyrl},
      title        = {{I}mproved {L}ong-{T}erm {S}urvival of {P}atients with
                      {R}ecurrent {M}edulloblastoma {T}reated with a
                      '{MEMMAT}-like' {M}etronomic {A}ntiangiogenic {A}pproach.},
      journal      = {Cancers},
      volume       = {14},
      number       = {20},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-02563},
      pages        = {5128},
      year         = {2022},
      abstract     = {Medulloblastoma (MB) recurrence is usually incurable
                      despite intensive therapy including high-dose chemotherapy.
                      An evolving alternative approach to conventional
                      chemotherapy aims at interfering with tumor angiogenesis at
                      different levels. We report on a novel combinatorial
                      metronomic antiangiogenic approach. The study is a
                      retrospective observational study of 29 consecutive patients
                      with first or multiple recurrences prospectively treated
                      according to the MEMMAT strategy ('MEMMAT-like') before the
                      formal protocol (MEMMAT; ClinicalTrials.gov Identifier:
                      NCT01356290) started. The study period was 11/2006 to
                      06/2016. Treatment consisted of daily oral thalidomide,
                      fenofibrate, celecoxib, and alternating 21-day cycles of
                      low-dose oral etoposide and cyclophosphamide supplemented by
                      IV bevacizumab and intraventricular therapy consisting of
                      alternating etoposide and liposomal cytarabine. Median
                      overall survival (OS) after recurrence for the whole group
                      was 29.5 months, OS was 48.3 ± $9.3\%$ at three years and
                      34.5 ± $8.8\%$ at five years, and progression-free survival
                      was 42.0 ± $9.5\%$ at three years and 29.4 ± $9\%$ at five
                      years. As of 07/2022, 9/29 patients are alive 86 to 164
                      months after the recurrence that prompted the 'MEMMAT-like'
                      therapy. Treatment was primarily out-patient and generally
                      well-tolerated. Toxicities did occur but were manageable. In
                      conclusion, antiangiogenic therapy according to the MEMMAT
                      strategy increased median OS of patients with recurrent MB
                      and may lead to long-term survival. Adherence to the
                      protocol, including intraventricular therapy, appears
                      important.},
      keywords     = {MEMMAT (Other) / antiangiogenic therapy (Other) /
                      bevacizumab (Other) / intraventricular therapy (Other) /
                      low-dose oral therapy (Other) / medulloblastoma recurrence
                      (Other) / metronomic therapy (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36291912},
      doi          = {10.3390/cancers14205128},
      url          = {https://inrepo02.dkfz.de/record/182306},
}